Evidence map›Paper›PMID 38650193›Full record

ReviewBioresources and bioprocessing2021

Zymomonas mobilis as an emerging biotechnological chassis for the production of industrially relevant compounds.

Adelaide Braga, Daniela Gomes, João Rainha, Cláudia Amorim, Beatriz B Cardoso, Eduardo J Gudiña, Sara C Silvério, Joana L Rodrigues, Lígia R Rodrigues

Abstract readReview
In one paragraph

Review in Bioresources and bioprocessing, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. A small number of point mutations confer formate tolerance inApplied and environmental microbiology · 2025
    Article
  5. Exploitation of Biodiversity in Bioeconomy: Examples, Opportunities, and Challenges.Advances in biochemical engineering/biotechnology · 2025
    Review
  6. Article
  7. Article
  8. Metabolic engineering ofFrontiers in bioengineering and biotechnology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Adelaide BragaCEB-Centre of Biological Engineering, Universidade Do Minho, Campus de Gualtar, 4710-057, Braga, Portugal.ORCID http://orcid.org/0000-0001-7432-0726
Daniela GomesCEB-Centre of Biological Engineering, Universidade Do Minho, Campus de Gualtar, 4710-057, Braga, Portugal.ORCID http://orcid.org/0000-0001-7703-2391
João RainhaCEB-Centre of Biological Engineering, Universidade Do Minho, Campus de Gualtar, 4710-057, Braga, Portugal.ORCID http://orcid.org/0000-0003-3963-234X
Cláudia AmorimCEB-Centre of Biological Engineering, Universidade Do Minho, Campus de Gualtar, 4710-057, Braga, Portugal.ORCID http://orcid.org/0000-0002-0999-0405
Beatriz B CardosoCEB-Centre of Biological Engineering, Universidade Do Minho, Campus de Gualtar, 4710-057, Braga, Portugal.ORCID http://orcid.org/0000-0003-3230-7659
Eduardo J GudiñaCEB-Centre of Biological Engineering, Universidade Do Minho, Campus de Gualtar, 4710-057, Braga, Portugal.ORCID http://orcid.org/0000-0002-3156-7363
Sara C SilvérioCEB-Centre of Biological Engineering, Universidade Do Minho, Campus de Gualtar, 4710-057, Braga, Portugal.ORCID http://orcid.org/0000-0003-3541-3908
Joana L RodriguesCEB-Centre of Biological Engineering, Universidade Do Minho, Campus de Gualtar, 4710-057, Braga, Portugal.ORCID http://orcid.org/0000-0002-3217-2320
Lígia R RodriguesCEB-Centre of Biological Engineering, Universidade Do Minho, Campus de Gualtar, 4710-057, Braga, Portugal. lrmr@deb.uminho.pt.ORCID http://orcid.org/0000-0001-9265-0630

Funding

Fundação para a Ciência e a Tecnologia POCI-01-0145-FEDER-029549Fundação para a Ciência e a Tecnologia SFRH/BD/04433/2020Fundação para a Ciência e a Tecnologia SFRH/BD/132324/2017Fundação para a Ciência e a Tecnologia SFRH/BD/138325/2018Fundação para a Ciência e a Tecnologia UIDB/04469/2020Fundação para a Ciência e a Tecnologia UMINHO/BPD/4/2019
6 · The paper itself

Abstract

Zymomonas mobilis is a well-recognized ethanologenic bacterium with outstanding characteristics which make it a promising platform for the biotechnological production of relevant building blocks and fine chemicals compounds. In the last years, research has been focused on the physiological, genetic, and metabolic engineering strategies aiming at expanding Z. mobilis ability to metabolize lignocellulosic substrates toward biofuel production. With the expansion of the Z. mobilis molecular and computational modeling toolbox, the potential of this bacterium as a cell factory has been thoroughly explored. The number of genomic, transcriptomic, proteomic, and fluxomic data that is becoming available for this bacterium has increased. For this reason, in the forthcoming years, systems biology is expected to continue driving the improvement of Z. mobilis for current and emergent biotechnological applications. While the existing molecular toolbox allowed the creation of stable Z. mobilis strains with improved traits for pinpointed biotechnological applications, the development of new and more flexible tools is crucial to boost the engineering capabilities of this bacterium. Novel genetic toolkits based on the CRISPR-Cas9 system and recombineering have been recently used for the metabolic engineering of Z. mobilis. However, they are mostly at the proof-of-concept stage and need to be further improved.

Indexed as

BioproductsIndustrial chassisMetabolic EngineeringSynthetic biologyZymomonas mobilis

Identifiers

PMID38650193
PMCPMC10992037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.